Beeh K M, Beier J, Esperester A, Paul L D
insaf Respiratory Research Institute, 65187 Wiesbaden, Germany.
Eur J Med Res. 2008 Dec 3;13(12):557-62.
Ambroxol is frequently used as mucolytic agent in respiratory diseases associated with increased mucus production like acute or chronic bronchitis. Further, ambroxol is used topically (lozenges) for the treatment of sore throat and pharyngitis associated with common cold. In addition to the effects of ambroxol on mucus regulation and local anaesthetic effects, a wide range of pharmacological antiinflammatory properties of ambroxol have been described in vitro and in vivo, including inhibition or scavenging of oxidative and nitro?sative stress, increase of local defense molecules involved in respiratory virus replication, reduction of proinflammatory cytokines and arachidonic acid meta?bolites, inflammatory cell chemotaxis, and lipid peroxidation of tissues. The present review summarizes the antiinflammatory effects of ambroxol and relates these properties to results from controlled clinical trials in targeted diseases such as chronic bronchitis, chronic obstructive pulmonary disease and sore throat.
氨溴索常用作黏液溶解剂，用于治疗与黏液分泌增多相关的呼吸道疾病，如急慢性支气管炎。此外，氨溴索还可局部使用（含片），用于治疗与普通感冒相关的咽喉痛和咽炎。除了氨溴索对黏液调节的作用和局部麻醉作用外，体外和体内研究均表明氨溴索具有广泛的药理抗炎特性，包括抑制或清除氧化应激和亚硝化应激、增加参与呼吸道病毒复制的局部防御分子、减少促炎细胞因子和花生四烯酸代谢产物、抑制炎症细胞趋化以及减轻组织脂质过氧化。本综述总结了氨溴索的抗炎作用，并将这些特性与慢性支气管炎、慢性阻塞性肺疾病和咽喉痛等目标疾病的对照临床试验结果相关联。
